Companies · Biotechnology

Aviir Inc

Irvine · Biotechnology

Diligence memoA one-page analyst read on Aviir Inc — recommendation, valuation, rhythm, risks.
$22.9M
Total raised · real
6
Rounds
2.7×
Latest step-up
Top 31%
Sector rank · raised
Series A
Latest stage · inferred · Mon Dec 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Aviir Inc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.81× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Aviir Inc is one of 4291 Biotechnology companies tracked from Irvine. By capital raised it ranks in the upper tier (ahead of 70% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2009-07-31 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2009Pre-Seed · 2009-10-06 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2009Series A · 2010-01-11 Raised $4.2M (real) Modeled valuation $152M (est)$4.2M$152MSeries A2010Series A · 2011-06-08 Raised $3.0M (real) Modeled valuation $108M (est)$3.0M$108MSeries A2011Series A · 2011-11-15 Raised $3.8M (real) Modeled valuation $136M (est)$3.8M$136MSeries A2011Series A · 2011-12-05 Raised $10M (real) Modeled valuation $362M (est)$10M$362MSeries A2011+$1.0M+$4.2M+$3.0M+$3.8M+$10MCumulative $23M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2009
Pre-Seed extension$1.0M · 2009
Series A$4.2M · 2010no Seed on file
Series A extension$3.0M · 2011
Series A extension$3.8M · 2011
Series A extension$10.0M · 2011

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$361.5M
Base estimate est.
$10.9M
Conservative case
$2.0B
Upside case
$45.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $55.2M · 2009-07-312009Pre-Seed · modeled $55.2M · 2009-10-06Series A · modeled $151.8M · 2010-01-11Series A · modeled $108.5M · 2011-06-08Series A · modeled $135.6M · 2011-11-15Series A · modeled $361.5M · 2011-12-052011
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
14.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$9.8M/yr
Capital velocity
16.9 yr
On record since
2009
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.2× above median
This company$22.9M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.8× above median
This company$10.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 5.6× above median
This company$361.5M
Sector median$64.2M

Raised more than 70% of sector peers (real $). Modeled value above 79% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #22 of 92.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Tobira Therapeutics, Inc. · Series A Raised $23.2M · modeled $513.3M (est)Neoprobe Corp · Series A Raised $14.0M · modeled $506.1M (est)Akebia Therapeutics, Inc. · Series A Raised $25.9M · modeled $504.1M (est)Adimab, LLC · Series A Raised $13.8M · modeled $499.5M (est)Elevation Pharmaceuticals Inc · Series A Raised $27.4M · modeled $448.3M (est)Mnemosyne Pharmaceuticals Inc · Series A Raised $24.0M · modeled $445.8M (est)Macrogenics Inc · Series A Raised $12.0M · modeled $434.4M (est)Neurologica Corp · Series A Raised $17.0M · modeled $433.8M (est)Bodymedia Inc · Series A Raised $20.1M · modeled $429.9M (est)Peloton Therapeutics, Inc. · Series A Raised $13.7M · modeled $423.0M (est)Seahorse Bioscience Inc · Series A Raised $20.7M · modeled $410.2M (est)Stemgent, Inc. · Series A Raised $37.9M · modeled $408.5M (est)Aviir Inc (this company) Raised $22.9M · modeled $361.5M (est)Aviir Inc
CompanyStageRaised · realValue · estvs peer med.
Tobira Therapeutics, Inc.Series A$23.2M$513.3M2.56×
Neoprobe CorpSeries A$14.0M$506.1M2.53×
Akebia Therapeutics, Inc.Series A$25.9M$504.1M2.52×
Adimab, LLCSeries A$13.8M$499.5M2.50×
Elevation Pharmaceuticals IncSeries A$27.4M$448.3M2.24×
Mnemosyne Pharmaceuticals IncSeries A$24.0M$445.8M2.23×
Macrogenics IncSeries A$12.0M$434.4M2.17×
Neurologica CorpSeries A$17.0M$433.8M2.17×
Bodymedia IncSeries A$20.1M$429.9M2.15×
Peloton Therapeutics, Inc.Series A$13.7M$423.0M2.11×
Seahorse Bioscience IncSeries A$20.7M$410.2M2.05×
Stemgent, Inc.Series A$37.9M$408.5M2.04×
Aviir Inc this companySeries A$22.9M$361.5M1.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2009-07-31$5.6M$55.2M90%
Pre-Seed$1.0M2009-10-06$5.6M$55.2M90%
Series A$4.2M2010-01-11$19.1M$151.8M90%
Series A$3.0M2011-06-08$13.6M$108.5M90%
Series A$3.8M2011-11-15$17.0M$135.6M90%
Series A$10.0M2011-12-05$45.5M$361.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2009-07-31
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$1.0M2009-10-06
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  3. Series A$4.2M2010-01-11
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 4.2× larger than the prior — scaling up.
  4. Series A$3.0M2011-06-08
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
  5. Series A$3.8M2011-11-15
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  6. Series A$10.0M2011-12-05
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
Intelligence
2012 ~Q2
Modeled next raise · ~6mo cadence
$26.7M
Modeled next size est.range $17.3M$42.7M
2.7×
Last step-up
$9.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Vijay Lathi7 other2009-07
Paul Klingenstein5 other2009-07
Douglas Harrington1 other2009-07
Thomas Quertermous1 other2009-07
Alex Komoroske2009-07
Alex S Komoroske2010-01
Bill Gerber2009-07
Bill S Gerber2010-01
David W. Rubin2011-12
Douglas S Harrington2010-01
John W. Campbell, III2011-06
Paul S Klingenstein2010-01
Thomas S Quertermous2010-01
Vijay S Lathi2010-01
Registry & provenance

Aviir Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1380324
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Proteogenix IncBiotechnologySeries A$8.0M$144.6Mnetwork1 shared operator · same sector · same stage
Aruna Biomedical IncBiotechnologySeries A$22.4M$480.5Msame sector · same stage
CyVek, Inc.BiotechnologySeries A$22.3M$361.5Msame sector · same stage
CircuLite IncBiotechnologySeries A$22.0M$415.7Msame sector · same stage
Mnemosyne Pharmaceuticals IncBiotechnologySeries A$24.0M$445.8Msame sector · same stage
Organovo Holdings, Inc.BiotechnologySeries A$24.0M$277.0Msame sector · same stage
Sound Pharmaceuticals IncBiotechnologySeries A$21.6M$304.0Msame sector · same stage
Aldeyra Therapeutics, Inc.BiotechnologySeries A$24.6M$361.5Msame sector · same stage
Frequently asked
How much funding has Aviir Inc raised?
Aviir Inc has raised approximately $22.9M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Aviir Inc's estimated valuation?
Provath's modeled valuation for Aviir Inc is approximately $361.5M (modeled range $10.9M–$2.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Aviir Inc at?
Aviir Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Dec 05.
What does Aviir Inc do and where is it based?
Aviir Inc operates in the Biotechnology sector, based in Irvine.
Explore related

See where Aviir Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Aviir Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.